- Studies Examine Use of Biomarkers in Patients with Risk Factors for Acute Kidney Injury
SAN DIEGO, March 16, 2015 /PRNewswire/ -- Astute Medical, Inc., developer of the NEPHROCHECK® Test, today previewed abstracts to be presented next week at the International Symposium on Intensive Care and Emergency Medicine (ISICEM). The research examines the use of two urinary biomarkers, tissue inhibitor of metalloproteinases (TIMP-2) and insulin-like growth-factor binding protein 7 (IGFBP-7), in relation to acute kidney injury (AKI) in post-operative patients and in patients exposed to nephrotoxic drugs.
"Previous studies have established TIMP-2 and IGFBP-7 as robust biomarkers for risk assessment of AKI, 1,2 a complex condition that stems from a variety of types of kidney insults,3" said Paul McPherson, Astute Medical chief scientific officer. "Continued study of different patient groups and medical situations associated with AKI is key to identifying the best uses of these biomarkers to aid in the management of susceptible patients."
As part of the scientific program investigators will present the following studies:
- Urinary TIMP-2 and IGFBP7 elevate early in critically ill postoperative patients that develop AKI (P287)
- AKI Biomarkers Offer Opportunity to Reduce Exposure to Nephrotoxic Drugs (P295)
Both studies used Astute Medical's NEPHROCHECK® Test, which is currently indicated only for risk assessment of AKI in specific patient populations.
About Astute Medical, Inc.
Selected to the 2014 Fierce 15 by Fierce Medical Devices, Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests.
The Company's focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.
Astute Medical is a founding corporate partner of 0by25, a human rights initiative aimed at eliminating preventable and treatable deaths from AKI worldwide by 2025.
Astute Medical's NEPHROCHECK® Test received 510(k)-clearance through the FDA's de novo classification process in September 2014. The test was CE-marked in 2012 and is available in Europe.
For additional information, please visit AstuteMedical.com.
For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see astutemedical.com/about/intellectual-property. PN0451 Rev A 2015/03/11
1 Kashani et al. Discovery and validation of cell-cycle arrest biomarkers in human acute kidney injury. Critical Care 2013,17:R25.
2 Bihorac A, et al. Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication. Am J of Respir Crit Care Med. 2014;189(8):932-939.
3 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter.,Suppl. 2012; 3:1-150.
SOURCE Astute Medical, Inc.